Novo Suffers Loss in Lawsuit Against Pharmacy’s Copycat Ozempic

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and weight loss drug participated in unlawful business practices.

The compounder, Wells Pharmacy Network LLC, presented “uncontroverted evidence that it ceased compounding and advertising” of its “Semaglutide + BPC-157,” therefore there is no controversy between the parties and the claims are moot, Judge Anne C. Conway for the US District Court for the Middle District of Florida ruled Wednesday.

“Wells Pharmacy has presented evidence that the advertisement was withdrawn and replaced on May 2, 2023—more than six months before Novo ...